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Abstract
Purpose:Cancer stem cells (CSC) are self-renewing tumor cells,
with the ability to generate diverse differentiated tumor cell
subpopulations. They differ from normal stem cells in the dereg-
ulation of the mechanisms that normally control stem cell phys-
iology. CSCs are the origin of metastasis and highly resistant to
therapy. Therefore, the understanding of the CSC origin and
deregulated pathways is important for tumor control.
Experimental Design: We have included experiments in vitro,
in cell lines and tumors of different origins.We have used patient-
derived xenografts (PDX) and public transcriptomic databases of
human tumors.
Results: MAP17 (PDZKIP1), a small cargo protein overex-
pressed in tumors, interactswithNUMB through thePDZ-binding
domain activating the Notch pathway, leading to an increase in
stem cell factors and cancer-initiating–like cells. Identical behav-
ior was mimicked by inhibiting NUMB. Conversely, MAP17
downregulation in a tumor cell line constitutively expressing this
gene led toNotchpathway inactivation and amarked reduction of
stemness. In PDX models, MAP17 levels directly correlated with
tumorsphere formation capability. Finally, in human colon,
breast, or lung there is a strong correlation of MAP17 expression
with a signature of Notch and stem cell genes.
Conclusions:MAP17 overexpression activates Notch pathway
by sequestering NUMB. High levels of MAP17 correlated with
tumorsphere formation and Notch and Stem gene transcription.
Its direct modiﬁcation causes direct alteration of tumorsphere
number and Notch and Stem pathway transcription. This deﬁnes
a new mechanism of Notch pathway activation and Stem cell
pool increase that may be active in a large percentage of tumors.
Clin Cancer Res; 23(14); 3871–83. 2017 AACR.
Introduction
MAP17 (DD96, PDZKIP1) is a small (17 kDa), nonglycosy-
lated membrane-associated protein located on the plasma mem-
brane and the Golgi apparatus (1–3) of the proximal tubule cells
of the kidney. It contains two transmembrane regions and a
hydrophobic C-terminus that encodes a PDZ-binding domain,
that allow its interaction with several PDZ domain–containing
proteins, like PDZK1 (4–7).
MAP17 overexpression enhances tumorigenic properties of
tumor cells, with increased proliferation, reduced apoptosis,
increased colony formation in soft agar, and increased growth
ratios in tumors in nude mice (8, 9). MAP17 is overexpressed in a
great variety of human carcinomas (10, 11). In many tumors,
including glioblastomas, lymphomas, and cervical, breast, pro-
state, and ovarian carcinomas, MAP17 overexpression is strongly
correlated with tumoral progression (7, 11, 12). While adenomas
and benign tumors, as well as normal tissues, rarely express
MAP17, a high proportion (50%–90%) of late-stage ormetastatic
tumors show high levels of MAP17, correlating with a more
dedifferentiated phenotype (7, 9, 12). These ﬁndings highlight
the relevance of this gene in tumorigenic process and tumor
development.
Increasing evidence has shown that Notch signaling regulates
aspects of asymmetric division and stemness (13). Aberrant
Notch signaling is found in most types of cancers, either carci-
nomas or those ofmesenchymal origin (14, 15). Notch activation
depends on the interaction of ligand receptors between neigh-
boring cells, being followed by g-secretase cleavage, releasing the
active form of the Notch intracellular domain (NICD). Upon its
release, NICD translocates to the nucleus, forming a ternary
complex with CSL and Mastermind-Like 1 (MAML1) to transac-
tivate its target genes, including HES and HEY gene families (13,
16). NUMB has an antagonistic inﬂuence on Notch pathway,
inhibiting Notch signaling by binding directly to the NICD
domain, thus preventing its access to the nucleus (17–20). NUMB
is also able to directly inhibit Notch by recruiting ITCH to
polyubiquitinate Notch (21).
Themechanism responsible for the increased tumorigenicity of
cells expressingMAP17 is not known yet. To precisely identify the
molecular mechanism induced by MAP17 that increases cell
tumorigenic properties, we performed a search for MAP17 part-
ners, ﬁnding that NUMB physically interacts with MAP17. This
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physical interaction leads to a mislocalization of NUMB, which
increases nuclear NICD, and consequent Notch pathway activa-
tion. As a consequence, MAP17-expressing cells increase the
presence of stem-related transcription factors along with the
stemness of tumor cells.
Materials and Methods
All methods were performed in accordance with the relevant
guidelines and regulations of the Institute for Biomedical
Research of Seville (IBIS, Seville, Spain) and University Hospital
Virgen del Rocio (HUVR, Seville, Spain).
Bacterial strains, yeast strains, and plasmids
MAP17, previously cloned into pBabe-puro (12), was cloned
into plasmid pGBKT7 using EcoRI-BamHI sites. To test MAP17
C-terminal deletions, an opal STOP codon was introduced by
mutagenic PCR in DNA sequence corresponding to amino acids
71, 102, and 110, obtaining the pGBKT7-MAP17FL, pGBKT7-
tMAP17, pGBKT7-MAP1770, andpBKT7-MAP17110 vectors. Trun-
cated MAP17 (tMAP17) was also obtained by mutagenic PCR in
pBabe-puro plasmids. NUMB was ampliﬁed from pCMV6-XL5-
NUMB (SC301023, Origene) and cloned into pGADT7 vector
using EcoRI-BamHI sites. As a result, MAP17 was fused to the
C-terminus of GAL4-binding domain and NUMB to the C-termi-
nus of GAL4 activation domain. All vectors were ampliﬁed using
E. coliDH5a strain. Y187 and Y2HGold yeast strainswere used for
yeast two-hybrid assays.
To downregulate NUMB expression, short hairpin RNA
(shRNA) against NUMB or scrambled sequence control in pB-RS
vectors were obtained from Origene (TR311064). Cells were
transfected with shRNA plasmids and selected with 2 mg mL1
of hygromycin. After selection, two of the four shRNAs against
NUMB were selected, shNb2 (TCAGCAGACAGGCATACA-
GAGGTTCCTAC) and shNb4 (shN in the text; ATCATTCCGTGT-
CACAACAGCCACTGAAC), after Western blot analysis and qPCR
analysis. MAP17 shRNA was previously described (22).
Yeast two-hybrid analysis
Y2HGold strain was transformed with all MAP17-expressing
fusion vectors, while Y187 strain was transformed with NUMB-
expressing fusion vector. Brieﬂy, yeast cells were diluted in 150 mL
of 35% PEG 5000, 0.2 mol/L lithium acetate, and 0.1 mol/L
dithiothreitol (DTT), transformed with 1 mg of each vector by
incubating the cells for 45minutes at 45C and centrifuged at 550
rpm. Y2HGold cells were plated in synthetic deﬁned (SD) medi-
um without Trp, while Y187 cells were plated in SD medium
without Leu. Colonies grew for 5 days at 30C. For mating,
Y2HGold-MAP17 cells were mixed with Y187-NUMB cells in
YPD and cultured for 3 days at 30C. Subsequently, cells were
resuspended in sterile water, after measuring OD600nm. This
allowed seeding a similar number of cells in SD plates in four
selective conditions: without Trp, Leu nor His; without Trp, Leu,
His nor Ade, and the same plates plus X-a-Galactose. Cells grew
for other 5 days at 30C.
Cell lines and cellular assays
T47D, HeLa, Calu3, and 293T cells were obtained from the
European Collection of Authenticated Cell Cultures (ECACC)
commercial repository at the beginning of this study. No further
authenticationwas performed in these cell lines. Commercial cells
were maintained in DMEM (Sigma) while AA, AX, and AW cells,
derived from sarcoma patients, were maintained in F10 medium
(Sigma). All cultures were supplemented with 10% FBS (Life
Technologies), penicillin, streptomycin, and fungizone (23).
Clonogenicity assays, Holo- and paraclone analysis (24), colonies
in soft agar, and tumorspheres analysis were performed as
described previously (25, 26).
Tumor samples
Tumor tissues were obtained via surgical resection of sarcomas
performed at Virgen del Rocio Hospital (Seville, Spain) after the
patient provided written informed consent according to a proto-
col approvedby the local ethics committee (CEI 2013/PI002). The
experiments were performed according to the European guide-
lines for laboratory animal care. This study was approved by the
IBIS Institutional Animal Care and Use Committee.
Patient-derived xenograft and the generation of sarcoma cells
Sarcoma patient-derived xenografts (PDX) were processed as
indicated in ref. 27. Upon reaching a size of 1,500 mm3, the mice
were euthanized, and the tumors were used to obtain cells to
perform tumorsphere experiment. Brieﬂy, tumors were cut in
small pieces and cultured in 6-cm2 plates with 1 mL of F10 for
24 hours, to allow the attachment of cells to the plate. After that,
another 2mL of F10mediumwas added to the plate, and the cells
grew for a week before performing the tumorsphere experiment,
as described before, using 10,000 cells per well. The investigator
was blinded to the data from MAP17 levels and therefore to the
outcome.
Protein isolation and nuclei puriﬁcation
Protein extracts and nuclei puriﬁcation for Western Blot anal-
ysis were obtained as described previously (25).
Coimmunoprecipitation and Western blot analysis
For coimmunoprecipitation assays andWestern blot detection,
antibodies againstNUMB(ab4147,Abcam)wereused at 1mg/mL.
For Western blot detection, we used MAP17 (MABC522, Merck,
1:500 dilution), Notch (Santa Cruz Biotechnology, s-6014-R,
1:200 dilution), and hnRNP C1/C2 (4F4; Santa Cruz Biotechno-
logy, sc-32308, 1:400 dilution) antibodies. a-Tubulin (T9026,
Translational Relevance
We report that the increase in MAP17 sequestrates NUMB,
leading to Notch pathway activation. As a consequence,
MAP17-expressing cells increase the stem-related transcription
factors along with the stemness of tumor cells. Therefore,
increased MAP17 levels might contribute in a causal form to
the progression of cancer by increasing the plasticity of the
cancer stem cell (CSC) compartment and by conferring higher
rates of conversion from progenitors to CSCs. This is the ﬁrst
time this new mechanism of tumor cell dedifferentiation to
CSChas beenproposed.Our experiments cover, in vitro, in cells,
in vivo and in human tumor samples, and conﬁrmed in direct
patient-derived xenografts and in many public transcriptomic
databases of human tumors. These are truly new ﬁndings that
explore a new pathway for Notch, and cancer stem cell activa-
tion, which may affect more than 50% of all tumors.
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Sigma) was used as a control. Horseradish peroxidase–labeled
rabbit anti-mouse (ab97046, Abcam, diluted 1:5,000) and goat
anti-rabbit (ab97051, Abcam, diluted 1:5,000) secondary anti-
bodies were used.
To detect MAP17–NUMB interaction, anti-NUMB antibodies
were incubated with protein G-Sepharose beads and incubated
at 4C for 3 hours. HeLa or T47D cell extract (2 mg; either
overexpressing MAP17 or not) were added to the beads in a
ﬁnal volume of 1 mL and incubated at 4C for 16 hours. The
beads were washed twice with RIPA buffer and once with cold
PBS. Western blot analyses were performed as described pre-
viously (28, 29).
NICD quantiﬁcation and proximity ligation assays
Cells were cultured onto glass coverslips in 6-well plates, for 36
hours, washed with PBS, and ﬁxed with PBS þ 4% paraformal-
dehyde for 20 minutes, and washed twice with PBS. Cells were
permeabilized with PBS þ 0.5% Triton X-100 for 5 minutes,
washed twice with PBS, and blocked with PBS þ 0.1% Triton
X-100þ 3% BSA for 30minutes at room temperature. Then, anti-
NUMB (ab14140, Abcam) or anti-NICD (ab8925, Abcam) were
added to cells, in 1mL of PBSþ 0.1% Triton X-100þ 3% BSA at a
ﬁnal concentration of 1 mg/mL and incubated at 4C for 6 hours
with gentle stirring. After that, samples incubated with anti-
NUMB were washed three times with PBS þ 1% Triton X-100
for 5 minutes each, and anti-MAP17 (9, 10), was added to cells
in 1 mL of PBS þ 1% Triton X-100 at a ﬁnal concentration of 2
mg/mL, being incubated overnight at 4C with gentle stirring.
After that, coverslips were washed four times with PBS þ 1%
Triton X-100 for 5 minutes each time, with a ﬁnal wash with
PBS for 5 minutes.
For NICD quantiﬁcation immunoﬂuorescence assays, Alexa
Fluor goat anti-rabbit IgG (A-11008, Life Technologies) was
added at a 1:250 dilution to the cells in 1 mL of PBS þ 0.1%
Triton X-100 þ 3% BSA and incubated in dark at room temper-
ature for 2 hours with gentle stirring. Cells were thenwashed three
times (5 minutes each) with PBS þ 0.1% Triton X-100. Finally,
coverslips were mounted on a slide with a drop of mounting
solution (Prolong Gold Antifade, Life Technologies) and dried.
NICD images were acquired with a Leica TCS-SP2-AOBS-UV
confocal microscope by sequential scanning of the emission
channels. Nuclear NICD was quantiﬁed using ImageJ software
and expressed as the ﬂuorescence in nuclei relative to the nor-
malized cytoplasm ﬂuorescence.
For proximity ligation assay (PLA) labeling, we followed man-
ufacturer's instructions (DUO92101, Sigma). Images were
acquired with a Leica TCS-SP2-AOBS confocal microscope. The
number of interactions between NUMB and MAP17 was quan-
tiﬁed using ImageJ software.
Analysis of gene transcription
Total RNA was puriﬁed as described previously (25).
To detect changes in gene expression, we used the following
probes, all from Life Technologies: MAP17 (Hs00906696_m1),
HES1 (Hs00172878_m1), HES5 (Hs01387463_g1), KLF7
(Hs00748636_s1), ID2 (Hs04187239_m1), GLI1
(Hs01110766_m1), KLF4 (Hs00358836_m1), SOX9
(Hs01001343_g1), NANOG (Hs04260366_g1), OCT4
(Hs00999632_g1), NUMB (Hs01105433_m1), and GAPDH
(Hs03929097_g1). Quantitative PCR was performed as
described previously (25).
FACS analysis
Labeling ofHeLAandT47Dcellswith antibodies againstCD44,
CD24, and CD133, and its detection by FACS was performed as
described previously (25).
Bioinformatics analysis
To detect correlations between MAP17 and genes related to
Notch pathway or stem cell genes, a total of 28 databases of
different tumors (breast, lung, colon, and cervix; Supplementary
Table S1) were analyzed using R2 software (Genomics Analysis
and Visualization Platform, http://r2.amc.nl). All datasets are
freely available in R2 webpage. To perform these correlations,
MAP17 (Pdzk1ip1, 219630_at) was used to ﬁnd correlations with
all the genes that appear in each database, ﬁxing a P value lower
than 0.05 to ﬁnd statistically signiﬁcant correlations. Probe
219630_at, which corresponds to MAP17, was used for all Affy-
metrix datasets, with the exception of TCGA and Budinska data-
sets, where we used the unique probe for MAP17 gene.
Transcriptomic analysis of MAP17 in human tumors
Correlations for MAP17 and associated genes were deter-
mined through analysis of the GSE34053, GSE20916,
GSE39395, GSE14773, Lung Adenocarcinoma TCGA 515 data-
set, and Tumor Breast Carcinoma TCGA 1097 public dataset
available at Gene Expression Omnibus. The public array anal-
yses were performed using the R package Bioconductor (http://
bioconductor.org). Our analysis tools incorporated function-
alities from several other R packages as follows: Geo Query,
AFFY, AFFYPLM, GENEFILTER, and LIMMA. For preprocessing,
we used AFFY tool applying rma methods for background
correction, quantile method for data normalization, PMonly
for PM–MM correction and median-polish for aggregation.
Differential gene expression was calculated using Bayesian
modeling provided by limma package tool. Adenocarcinoma
TCGA 515 dataset and Tumor Breast Carcinoma TCGA 1097
were analyzed by automatized tools provided at Oncomine
(Compendia Biosciences, www.oncomine.org), R2: Genomics
Analysis and Visualization Platform (http://r2.amc.nl/).
Results
MAP17 physically interacts with NUMB
To precisely identify the molecular mechanism induced by
MAP17 that increases the tumorigenic properties of cells, we
performed a yeast two-hybrid screening for MAP17 partners,
identifying NUMB as MAP17 interactor. To conﬁrm this physical
interaction in cells, we overexpressed full-length MAP17 and
immunoprecipitated it with NUMB antibodies, ﬁnding that
MAP17 also binds to NUMB in human cells (Fig. 1A).
To characterize MAP17–NUMB interaction, we generated
several mutants of MAP17 by cutting different regions of the
C-terminus, which contain the PDZ-binding domain (Fig. 1B).
Two of these mutants were speciﬁc for the PDZ-binding
domain. MAP17(1–110) lacked only the last 4 amino acids,
and MAP17(1–101) lacked the last 13 amino acids. Further-
more, we generated a MAP17(1–70) mutant lacking the entire
intracellular region of MAP17. We then explored their interac-
tion with NUMB in using yeast two-hybrid system interactions
(Fig. 1C). We found that MAP17–NUMB interaction was dis-
rupted only for MAP17(1–101) and MAP17(1–70) mutants,
MAP17(1–101) being the mutant lacking the smallest region
MAP17 Activates Notch
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unable to bind NUMB, so we referred to it as tMAP17 (trun-
cated MAP17) in the following sections.
To conﬁrm the MAP17–NUMB interaction in cell, we used the
in situ PLA which allows direct detection of in vivo protein inter-
actions with high speciﬁcity and sensitivity. Protein interaction
can be readily detected and localized with single molecule reso-
lution and objectively quantiﬁed in vivo (30). To this end, we
overexpressed the vector only (EV), MAP17, or tMAP17 in HeLa
and T47D cells (Fig. 1D; see also Supplementary Fig. S1). After
selection, we performed an in situ PLA and found a clear interac-
tion of MAP17 with NUMB; however, this interaction was not
detected with tMAP17 (Fig. 1E and F).
MAP17 oncogene overexpression activates the Notch
pathway
Next, we examined the functional relevance of this interaction.
NUMB antagonizes Notch signaling activities by the ubiquitina-
tion of the membrane-bound Notch receptor and the subsequent
degradation of NICD following receptor activation. Therefore, if
MAP17 has a functional role involving NUMB, its overexpression
should alter Notch pathway. To determine this, we measured
NICD nuclear levels by immunoﬂuorescence in cells overexpres-
sing MAP17, EV, or tMAP17 using NICD antibodies (Fig. 2A). We
observed an increased intensity of NICD in the nucleus of cells
overexpressing MAP17, showing in EV or tMAP17 cells a similar
lower intensity of nuclear NICD, as was conﬁrmed after nuclear
signal quantiﬁcation by ImageJ software (Fig. 2B).
To conﬁrm this ﬁnding, we performed nuclear fractionation,
and levels of nuclear NICDwere determined, detecting that nuclei
of MAP17-expressing cells contained more nuclear NICD than
control cells (Fig. 2C).
In addition to the known HES1 gene as target of Notch
pathway, other target genes also include HES5, KLF7, and ID2
(31). Furthermore, the Notch target HES1 is a repressive tran-
scription factor that binds the ﬁrst intron of GLI1 and inhibits its
expression (32). We measured the levels of these Notch-depen-
dent transcripts in EV, MAP17, or tMAP17 cells, ﬁnding increased
transcripts levels of HES1 and HES5 in MAP17-expressing cells
compared with expression in EV and tMAP17 cells (Fig. 2D).
Furthermore, genes that should be repressed under Notch acti-
vation, such as KLF7 and GLI1, showed lower levels of transcrip-
tion in MAP17-expressing cells (Fig. 2D). These results were
identical in both cell lines, conﬁrming thatMAP17overexpression
activates Notch pathway. Only ID2 showed a different behavior,
showing the expected decrease in transcription only for HeLa cells
and an increment in T47D cells, maybe due to cell line–speciﬁc
reasons.
MAP17 oncogene overexpression activates the CSC
phenotype
Notch target genes have been connected with the maintenance
of the cell's potential for self-renewal, suggesting that Notch
pathway activation triggers the production of stem transcription
factors (33). Cancer stem cells (CSC), or cancer-initiating cells,
show an increase in stem cell factors, such as OCT4, NANOG,
SOX9, and KLF4 (34, 35). Therefore, we analyzed the effect of
MAP17 overexpression on these CSCmarkers, observing that cells
overexpressing MAP17 contained signiﬁcantly increased mRNA
levels of all these stem cell transcripts (Fig. 3A).
To conﬁrm the cancer stem–like phenotype of MAP17-expres-
sing cells, we measured cellular subpopulations showing CSC
surface markers. T47D is a mammary tumor cell, its CSC
Figure 1.
NUMB interacts in vivo with the
C-terminal domain of MAP17. A,
Coimmunoprecipitation of NUMB-
MAP17 obtained from HeLa or T47D cell
extracts transfected with EV or MAP17.
B, The four MAP17 genes used for Y2H
assays. For MAP17-FL, the last four
amino acids (C-terminal PDZ-binding
domain) are highlighted. C, Yeast two-
hybrid analysis (Y2H) results showing
positive interaction betweenNUMB and
the C-terminal domain of MAP17. The
deletion of 13 amino acids in C-terminal
domain breaks the interaction between
both proteins (–HWL: plates without
histidine, tryptophan, or leucine, -Ade:
without adenine). D, Expression of
MAP17 measured by qPCR assays. E,
Confocal microscopy of PLA of HeLa or
T47D cells transfected with EV, MAP17,
or tMAP17 vectors. F, Number of PLA
events per cell, showing statistically
signiﬁcant differences between cells
overexpressing MAP17 relative to EV or
tMAP17 cells. All experiments were
repeated a minimum of three
independent times in triplicate. Student
t test statistical analysis of the data was
performed to ﬁnd statistical differences
( , P < 0.01;  , P < 0.001). EV, empty
vector; M17, full-length Map17; tM17,
truncated MAP17; Nb, NUMB.
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Figure 2.
MAP17 overexpression increases NICD levels in nuclei. A, Confocal microscopy of HeLa or T47D cells transfected with EV, MAP17, or tMAP17 vectors. Arrowheads
indicate individual cells with higher nuclear NICD. B, Relative ﬂuorescence of nuclei normalized to cytoplasm ﬂuorescence of individual cells was determined for
a minimum of 180 cells from each condition. Cells overexpressing MAP17 showed signiﬁcantly higher levels of nuclear NICD (P < 0.05). C, NICD nuclear
distribution detected byWB in HeLa or T47D cells transfected with EV, MAP17, or tMAP17 vectors.D, qPCR analysis of Notch pathway genes in HeLa and T47D cells.
The results are the average of at least four independent experiments performed in triplicate samples. Student t test statistical analysis of the data was
performed to ﬁnd statistical differences ( , P < 0.05;  , P < 0.01;  , P < 0.001). EV, empty vector; M17, full-length Map17; tM17, truncated Map17.
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subpopulation described as CD44þ/CD24 (28, 36), while HeLa
CSC subpopulation has been described as CD133þ. Therefore, we
measured these subpopulations in EV, MAP17, or tMAP17 cells.
Both in HeLa- and T47D-overexpressing MAP17 cells, we found
an increase in these surfacemarkers comparedwith EV or tMAP17
cells (Fig. 3B and C).
Figure 3.
Overexpression of MAP17 increases
CSC markers. A, qPCR analysis of stem
cell genes in HeLa and T47D cells. The
results are the average of at least four
independent experiments performed in
triplicate samples. B, Analytic FACS to
identify the CD133þ subpopulation for
HeLa cells. C, Analytic FACS to identify
the CD44þ/CD24 subpopulation for
T47D cells. D, HeLa and T47D cell
tumorspheres. E, Percentage and area
of the tumorspheres obtained from
HeLa or T47D cells, showing thatMAP17
overexpression induces a higher
percentageof tumorspheres in both cell
lines. F, Bright-ﬁeld microscopy of a
typical holoclone, meroclone, or
paraclone of HeLa or T47D cells. G,
Percentage of each type of clone. At
least 150 individual clones, in triplicate,
were analyzed. Student t test statistical
analysis of the data was performed to
ﬁnd statistical differences ( , P < 0.05;
 , P < 0.01;  , P < 0.001). EV, empty
vector; M17, full-length Map17; tM17,
truncated Map17. H, Effects of MAP17
knockdown by shRNA in Calu3 cells.
shRNA directed against MAP17
efﬁciently downregulates MAP17
expression in Calu3 cells, measured by
qPCR. I, qPCR analysis of Notch
pathway genes in Calu3 cells
expressing scrambled RNA (scr) or
shRNA directed against MAP17 mRNA
(shMAP17). The results are the average
of at least three independent
experiments. J, qPCR analysis of stem
cell genes in Calu3 cells. K, shRNAs
directed against MAP17 increases the
number of holoclones. L, Percentage of
tumorspheres obtained from Calu3
cells, showing that MAP17
downregulation induces a lower
number of tumorspheres. The results
are the average of at least three
independent experiments. Student t
test statistical analysis of the data was
performed to ﬁnd statistical differences
(, P < 0.05;  , P < 0.01;  , P < 0.001).
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To analyze the possible role of increased MAP17 levels on the
CSCphenotype,we alsomeasured the formationof tumorspheres
and clonal growth, commonly associated to the cancer-initiating
cell phenotype and the ability to generate new colonies. The last
experiment allows distinguishing between holoclones, cells con-
sidered derived from stem cells; paraclones, differentiated cells
incapable to reconstitute a culture; and meroclones, with inter-
mediate properties between holo- and paraclones (24, 26, 37).
Human tumor cell populations can be maintained in serum-free
suspension cultures, growing as clusters of cells called "tumor-
spheres" (38). These tumorspheres display some self-renewal
ability upon disaggregation, being enriched with multi-potent
epithelial progenitors (34) and an increase in the expression of
CSCmarkers (35). Therefore, wemeasured whether MAP17 over-
expression alters the ability of tumor cancer cell lines to form
tumorspheres.
EV, MAP17, or tMAP17 cells were subjected to disaggregation.
The resulting single-cell suspensionwas seeded in completemedia,
allowing to grow during 5 days to form tumorspheres (Fig. 3D). In
both cell lines, the number of tumorspheres was signiﬁcantly
increased only in MAP17-overexpressing cells (Fig. 3E).
Cell lines generated from carcinomas consistently produce
in vitro colony patterns similar to those produced by the stem
cells of normal epithelia. On the basis of the different types of
colony morphologies formed, it is possible to predict some
stem cell characteristics (24). Several ﬁndings now suggest that
malignant cell lines may in fact retain patterns of stem cell
behavior (37, 39–41). For example, malignant cell lines
derived from holoclones contain subpopulations of cells with
putative stem cell characteristics (24, 37). Therefore, we mea-
sured whether MAP17 overexpression alters the ability of both
cancer cell lines to form holoclones. Trypsinized cells were
seeded at low density and grew for 14–20 days. After that, we
analyzed the phenotypic characteristics of the individual col-
onies and the holoclones counted, observing a signiﬁcant
increase holoclone percentage due to MAP17 overexpression
(Fig. 3F and G).
The increase inCSCproperties in cells with highMAP17 should
correlate with a higher number of colony-initiating cells. There-
fore, wemeasured the number of colonies formed after seeding of
cells at a very low density (Supplementary Fig. S2). As expected,
based on previous results, MAP17-expressing cells formed more
colonies than EV or tMAP17. This was also true for colony
formation in soft agar (Supplementary Fig. S3).
In summary, these results show that, in human tumor cells,
MAP17 overexpression induces the expression of CSCphenotype,
which could be responsible for an increase in the stem cell–like
properties.
MAP17 downregulation decreases Notch pathway activation
and stemness features
To further evaluate the role of MAP17 expression, we selected
Calu3, a tumor cell line with endogenous high levels of MAP17,
and downregulated its expression by shRNA ectopic expression
(Fig. 3H). We measured Notch pathway activity and the physi-
ologic behavior associated with MAP17 decrease in Calu3 cells,
observing changes in levels of Notch-dependent transcripts (Fig.
3I), conﬁrming the relevance of MAP17 expression in Notch
pathway activation. In addition,MAP17 downregulation induced
a clear reduction in all CSC transcription markers, conﬁrming the
functional relationship between MAP17 and stemness (Fig. 3J).
Finally, when MAP17 was downregulated in Calu3 cells, we
observed an obvious reduction in the associated stemness phe-
notype, with a signiﬁcant decrease both in holoclone and tumor-
sphere numbers (Fig. 3K andL). These results also conﬁrm that the
maintenance of high MAP17 levels is important in maintaining
the CSC phenotype.
Downregulation of NUMB mimics MAP17 overexpression
If MAP17 overexpression is functionally connected to NUMB
sequestration, then NUMB downregulation should mimic
MAP17 overexpression. We tested the effect of NUMB down-
regulation both in Notch pathway activation and stem cell–like
behavior of tumor cells. To do this, we constitutively overex-
pressed shRNA against NUMB in the same tumor cell lines,
showing a decrease in both mRNA and protein levels (Fig. 4A
and B). To avoid off-target effects, we analyzed two different
shRNA against NUMB, with similar results (Supplementary Fig.
S4). Like in MAP17-overexpressing cells, we observed an increase
in Notch pathway activation (Fig. 4C). NUMB downregulation
also increased mRNA levels of stem cell factors, correlated with
increased colony formation (Fig. 4D and E). In addition, we also
observed an increase in holoclone and tumorsphere numbers
(Fig. 4F and G).
Finally, to conﬁrm the CSC-like phenotype with downregu-
lated NUMB cells, we measured the cellular subpopulations
showing CSC surface markers, as was done with the MAP17-
expressing cells. We found that HeLa and T47D cell expressing
NUMB shRNA showed a higher percentage of CD133þ and
CD44þ/CD24 cells, respectively, conﬁrming that NUMB down-
regulation is equivalent to MAP17 overexpression in its ability to
induce a CSC-like phenotype (Fig. 4H).
Taken together, these data indicate that NUMB sequestration is
sufﬁcient to activate Notch pathway and increase the stem cell–
like properties of tumor cells, pointing a possible role ofNUMBas
tumor suppressor by reducing Notch pathway activation and the
stemness properties of tumor cells.
MAP17expression correlatedwithhigh tumorsphere formation
in low-passage sarcoma cells and tumors directly from PDX
models
To approach our ﬁndings in a more in vivo situation, we took
low passaged sarcoma cell lines generated in our laboratory
directly from sarcoma tumors. The lines have been propagated
no longer than 20 passages, so the number of genetic alterations
should be lower compared with lines such as HeLa, highly
propagated during years.
AA and AW lines, with very low levels of MAP17, and AX line,
with low levels of MAP17, were transfected to force its MAP17
constitutive overexpression. In addition, we overexpressed
MAP17 shRNA in AX cell line, with endogenous MAP17 expres-
sion. After selection, 5,000 cells were seeded to measure the
number and size of tumorspheres. We observed that, in all
cases, MAP17 overexpression produced a higher number and
increased size of tumorspheres in these low-passage sarcoma
cell lines (Fig. 5A).
Like for T47D and HeLa cells, mRNA levels from either
Notch pathway and stem cell genes were highly activated in
cells with high levels of MAP17 (Fig. 5B, black and dark gray
bars).
Finally, we took 5 models of PDXs of sarcoma growing in
mice. After tissue disaggregation, we directly measured MAP17
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Figure 4.
shRNA directed against NUMB (shN)
efﬁciently downregulates NUMB expression,
both in HeLa (A) and T47D (B) cells,
measured by qPCR and Western blot (WB).
C, qPCR analysis of Notch pathway genes in
HeLa and T47D EV cells. D, qPCR analysis of
stem cell genes in HeLa and T47D EV cells.
The results are the average of at least four
independent experiments. E, Clonogenicity
assays of HeLa and T47D EV cells with
scrambled or shN shRNA.One thousand cells
were seeded in 10-cm2 plates in triplicate
and cultured for 14–20 days at 37C with 5%
CO2. Overexpression of shN induces a
signiﬁcantly higher number of clones
relative to the number in cell populations
overexpressing scrambled shRNA. The
results are the average of at least three
independent experiments performed in
triplicate samples. Student t test statistical
analysis of the data was performed to ﬁnd
statistical differences ( , P < 0.05;
 ,P<0.01; , P<0.001).F, shRNAdirected
against NUMB increases the number of
holoclones, mimicking the effect induced by
MAP17 overexpression. G, Percentage and
area of the tumorspheres obtained from
HeLa or T47D cells, showing that decrease of
NUMB induces a higher number of
tumorspheres in both cell lines. H, Analytic
FACS to identify the CD44þ/CD24
subpopulation for T47Dcells and theCD133þ
subpopulation for HeLa cells. The graph
shows the average of three independent
experiments performed in triplicate. Student
t test statistical analysis of the data was
performed to ﬁnd statistical differences
( , P < 0.05;  , P < 0.01;  , P < 0.001).
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levels and seeded 10,000 cells to measure the number of
tumorspheres (Supplementary Table S2). When plotted to
establish one-to-one correlation, we found a strong direct
correlation of tumorsphere numbers and MAP17 levels for
each tumor (Fig. 5C, R2¼0.8206). In these tumorspheres from
primary sarcomas, we also measured the activation of the
Notch pathway and the Stem cell–related factors, correlating
their levels to the MAP17 levels. We observed a clear correla-
tion between the MAP17 levels and the activation of the Notch
pathway and the activation of the Stem cell–related factors
(Fig. 5D).
All these data strongly suggest that MAP17 drives Notch path-
way activation, tumorsphere formation, and activation of the
stem cell transcription machinery.
Figure 5.
MAP17 overexpression activates stem cell–like phenotype and Notch pathway. A, Sarcoma cell lines transfected to overexpress MAP17 (AA, AW, and AX) or
to knock down MAP17 expression (AX) were cultured as tumorspheres, measuring both its number and area. Red, number of tumorspheres; blue,
area of tumorspheres. B, qPCR analysis of Notch pathway and stem cell genes in sarcoma cell lines. The graphs show the average of three independent
experiments performed in triplicate. White bars, EV; black bars, MAP17 overexpression; dark gray bars, scrambled shRNA; light gray bars, shN shRNA
overexpression. Student t test statistical analysis of the data was performed to ﬁnd statistical differences ( , P < 0.05;  , P < 0.01;  , P < 0.001). C, Sarcoma
cells, derived from explants grown in mice, were seeded directly and grown as tumorspheres, connecting the number of tumorspheres with MAP17
expression. The graphs show the average of three independent experiments performed in triplicate. D, Sarcoma cells, derived from explants grown
in mice, were seeded directly and grown as tumorspheres, and the mRNA levels of MAP17 were analyzed, as well as those of HES1, GLI1, OCT4, KLF4, NANOG,
and SOX9. These genes were correlated individually with the levels of MAP17. The graphs show the average of three independent experiments performed
in triplicate. E, Expression of Notch pathway–related genes and Stem cell genes in lung, cervix, breast, and colon tumors, extracted from R2 analysis.
Red indicates positive correlation between a speciﬁc gene and MAP17, whereas blue indicates negative correlations. The higher the intensity of the
color, the greater number of datasets showing the same correlation.
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MAP17 expression correlatedwithNotchpathway andStem cell
gene transcription in human tumors
To correlate MAP17 with Notch pathway and stem cell gene
transcription, we performed meta-analysis of 28 different public
databases of transcriptome from tumors, 6 from lung tumors, 2
from cervix, 10 from breast, and 10 from colon (Supplementary
Table S1).
From all these databases, we analyzed correlation of MAP17
expression with Notch pathway genes and stem cell genes. Only
genes with P < 0.05 were considered (Supplementary Figs. S5 and
S6), and from then, only those geneswith homogeneous behavior
among all databases were taken further (Fig. 5E). We observed a
clear set of genes positively (red) or negatively (blue) correlated
with MAP17 expression either among the Notch pathway or the
Stem cell gene machinery (Fig. 5E). Among these genes are the
genesmeasured previously as end points or markers of the routes,
clearly and robustly supporting the relation of MAP17 with the
Notch pathway activation in vivo.
Finally, GSE34053database, from colon tumors, have transcrip-
tion of sorted CD133þ cells. We can observe that CD133þ cells
carry higherMAP17 expression alongwithmoreHES1, OCT4, and
SOX9 (Fig. 6A). We also observed a clear correlation between the
expression levels of MAP17 and HES1 (r ¼ 0.560), OCT4 (r ¼
0.828), SOX9 (r¼ 0.858), andCD133þ expression (Fig. 6B andC).
Similar correlationswereobserved for lungadenocarcinomaTCGA
database of (Fig. 6D and E), and breast adenocarcinoma TCGA
database (Fig. 6F and G).
Because MAP17 is overexpressed in a high percentage of
tumors, Notch pathway is activated in these cells increasing the
percentage of cancer-initiating cells. This deﬁnes a new mecha-
nismofNotch pathway activation and Stemcell pool increase that
may be active in a large proportion of tumors.
Discussion
Notch signaling pathway, a critical pathway governing embry-
onic development, is involved in the maintenance of tumor
stemness and cancer metastasis. Increased activity of the Notch
pathway has been reported in a variety of tumor cell lines and in
tumors of different origin, including lung, colon, breast, and
prostate tumors and sarcomas, melanomas, leukemias, and lym-
phomas (42–47). In these studies, Notch activity also appeared to
participate in cancer metastasis by modulating the epithelial–
mesenchymal transition (EMT), the tumor angiogenesis process-
es, and the anoikis resistance of tumor cells (48–50).
MAP17 is repressed inmost tissues but is activated in tumors as
a consequence of progressive demethylation (51) and/or onco-
genic activation of the promoter (10). Therefore, MAP17 levels
accumulate as a tumor grows. By sequestering NUMB, MAP17
allows nuclear localization of NICD and its transcriptional acti-
vation, increasing the stemness of cancer cells. By modulating
Notch, MAP17 may also increase metastasis, contributing to the
malignancy of these tumors. Our data clearly show that upon
MAP17 expression, the Notch pathway is activated and, therefore,
also the stemness of tumor cells. Because MAP17 is prevalent in
approximately 50% of tumor types (7), our data suggest that half
of tumors might have an activated Notch pathway, this activation
being independent of the canonical protease activation of the
receptor. Furthermore, our own data (Supplementary Fig. S7)
suggest that these cells with activatedMAP17 aremore dependent
on the Notch pathway activation, as these cells with high levels of
MAP17 are more sensitive to the Notch inhibitor DAPT (Supple-
mentary Fig. S7). Because of its small size and structure, MAP17 is
unlikely a good target, but we have previously observed that
MAP17-expressing cells are more sensitive to the proteasome
inhibitor bortezomib (27, 52). It will be interesting to test
proteasome inhibitors to study possible synergisms or antagon-
isms with different Notch inhibitors.
Upon interaction with a ligand, Notch undergoes two proteo-
lytic cleavages that result in signal transduction activation (53, 54).
These cleavages result in the release of active NICD and its nuclear
translocation. Thus, NICD joins a multiprotein transcriptional
complex, integrating MAML1 and CSL1 (55, 56), required for
Notch-mediated transcriptional regulation. Notch signaling per-
sists until NICD is phosphorylated by CDK8 and targeted for
proteasomal degradation (57). NUMB promotes the degradation
ofNICD following receptor activation, targeting it for proteasomal
degradation, and preventing its translocation to the nucleus acting
as a tumor suppressor (20, 58). Therefore, sequestration of NUMB
allows for an increase in NICD and its transcriptional activity.
MAP17 overexpression, a protein not present in most somatic
cells, but commonly deregulated in tumors (7, 9, 10), binds and
sequestrates NUMB, activating Notch pathway and allowing
nuclear NICD translocation. Therefore, through this mechanism,
MAP17-expressing tumors activate Notch-dependent pro-prolif-
erative genes and repress Notch-dependent tumor suppressor
genes (Supplementary Fig. S8).
Through our described NUMB sequestration by MAP17, a
complete set of stem cell factors, such as SOX9, KLF4, NANOG,
and OCT4, showed an increased transcription, increasing cell
percentage with CSC-like physiology. MAP17 is frequently over-
expressed in advanced stage tumors, correlating with higher levels
of cancer-initiating cells. We can now suggest that these higher
numbers of CSC-like cell populations are the consequence of
Notch pathway activation caused by MAP17 expression.
In mammalian cells, NUMB acts as an adapter between NICD
and the E3 ubiquitin ligase ITCH (21, 59). It has been proposed
that NUMB intracellular levels may act as a molecular sensor that
determines Notch fate and, hence, the responsiveness of cells to
Notch ligands (20). Deregulation of this Notch switch by MAP17
overexpression may lead to unwanted deregulation of stem cell
properties. Similar effects have been reported for the E3-ligase
Siah1 and LNX. The E3-ligase Siah1 binds and ubiquitinates
NUMB, leading to its proteasomal degradation (60). SIAH1 over-
expression causes the relocalization of NICD from the cell surface
to the nucleus, which is indicative of Notch activation. Similar
results were obtained for the E3-ligase, LNX, which also targets
NUMB for ubiquitin-dependent degradation (61).
In both breast cancers and NSCLCs, loss of NUMB expression is
due to its exaggerated ubiquitination and ensuing degradation
without genetic alterations in NUMB locus and normal mRNA
levels (58, 62). The genetic lesion upstream of NUMB in these
tumors remains unknown. It is tempting to speculate that MAP17
is responsible for these effects because a wide expression screening
ofE3-ligases inbreast cancerdidnot reveal alterations immediately
compatible with NUMB status of these cancers (63). Reduced
NUMB levels also correlate with poor prognosis in salivary gland
carcinomas, although no additional molecular or mechanistic
details are currently known for these tumors (64). Inbreast tumors,
NUMBexpression is frequently lost (58). This event correlateswith
a poor prognosis (65), a less-differentiated phenotype compared
with NUMB-expressing tumors (58, 65, 66), and CSC marker
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Figure 6.
A, GSE34053 database, from colon tumors, have transcription of sorted CD133þ cells. We analyzed the correlation of CD133þ cells with MAP17 expression
along with more HES1, OCT4, and SOX9. B, We observed a clear correlation between the expression levels of MAP17 and HES1 (r ¼ 0.560), OCT4 (r ¼ 0.828),
SOX9 (r ¼ 0.858), and CD133þ expression (Pearson correlation). C, Heatmap showing these correlations in CD133-sorted cells. D and E, Similar correlations
were observed for lung adenocarcinoma TCGA database, and breast adenocarcinoma TCGA database (F and G; in this case, with the CD44þ membrane marker).
 , P < 0.05;  , P < 0.01;  , P < 0.001.
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expression (66). This latter result is interesting in light of the recent
ﬁnding that poorly differentiated breast tumors harbor a higher
CSC-content than well-differentiated tumors (67). Furthermore,
an in vivo RNA interference screen in a mouse lymphomagenesis
model identiﬁed NUMB as a putative tumor suppressor whose
ablation can accelerate the onset of lymphomas (68).
Therefore, the oncogenic function ofMAP17 is easily explained at
thebiochemical andmolecular level by the role ofNUMBasaNotch
pathway inhibitor. In the absence of NUMB, Notch pathway is
activated, with pro-proliferative and antidifferentiative effects (20),
In summary, we report here that NUMB interacts with the C-
terminal domain of MAP17. This physical interaction leads to an
increase in nuclear NICD and consequent Notch pathway acti-
vation. As a result, MAP17-expressing tumor cells have an
increased stem-related transcription factors along with a higher
stemness. Increased MAP17 levels might therefore additionally
contribute to the progression of cancer by increasing the plasticity
of the CSC compartment and by resulting in higher rates of
conversion from progenitors to CSCs.
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